- Conditions
- Solid Tumors, Neoplasms
- Interventions
- Mocertatug rezetecan
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 9,520
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- BIIB092, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
- Conditions
- Urinary Incontinence, Urge, Fecal Incontinence
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
- Drug · Procedure · Other
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
- Interventions
- CPAP
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,062 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Aortic Aneurysm, Abdominal
- Interventions
- GORE® EXCLUDER® Conformable AAA Endoprosthesis
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- E2814, Lecanemab, Matching Placebo (E2814)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
- Interventions
- Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137
- Biological · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
- Conditions
- Concussion, Convergence Insufficiency
- Interventions
- Standard Community Concussion Care (SC), SC plus Simple Convergence Exercises (SC+), SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)
- Behavioral
- Lead sponsor
- Mitchell Scheiman
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Fullerton, California • Palo Alto, California + 5 more
- Conditions
- Breast Cancer
- Interventions
- brachytherapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
- Conditions
- Diabetic Polyneuropathy
- Interventions
- Thioctic Acid, Placebo
- Drug
- Lead sponsor
- MEDA Pharma GmbH & Co. KG
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 21 more
- Conditions
- Cervical Cancer
- Interventions
- oxaliplatin
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- Vasomotor Symptoms (VMS)
- Interventions
- MT-8554
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Tumor
- Interventions
- Sunitinib, Surgery
- Drug · Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Myocardial Infarction
- Interventions
- CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo
- Biological · Drug
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 27 more
- Conditions
- Orthopaedic Trauma Fractures and Non-unions
- Interventions
- Reamer-Irrigator-Aspirator (RIA)
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Glaucoma
- Interventions
- Usual Care + Health Promotion Intervention
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
- Conditions
- Weight Loss
- Interventions
- Weight Loss Only, Weight Loss Plus
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years to 70 Years · Female only
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Leukemia
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
- Conditions
- Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers
- Interventions
- Freenome test
- Diagnostic Test
- Lead sponsor
- Freenome Holdings Inc.
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 48,995 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 147
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 122 more
- Conditions
- COVID-19
- Interventions
- Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
- Drug · Biological
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Davis, California • Irvine, California + 30 more